A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Clinical trial NCT06968585 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06968585
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-18
- Primary completion
- 2026-11-30
- Enrollment
- 365
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.